Longeveron (LGVN) Long-Term Deferred Tax (2021 - 2022)
Longeveron's (LGVN) quarterly Long-Term Deferred Tax came in at $6.1 million in Q4 2022, down 16.09% year-on-year from $7.3 million in Q4 2021, and down 16.09% quarter-over-quarter from $7.3 million in Q4 2021.
Longeveron (LGVN) Long-Term Deferred Tax (2021 - 2022) Analysis & Trends
Longeveron's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $6.1 million for Q4 2022.
- On a quarterly basis, Long-Term Deferred Tax fell 16.09% year-over-year to $6.1 million in Q4 2022; TTM through Dec 2022 was $6.1 million, a 16.09% decrease from a year earlier, with the FY2022 full-year figure at $6.1 million, down 16.09% from the prior year.
- Long-Term Deferred Tax fell to $6.1 million in Q4 2022 per LGVN's latest filing, from $7.3 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $7.3 million in Q4 2021 and bottomed at $6.1 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 6.10 Mn |
| Dec 31, 2021 | 7.27 Mn |